Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-103)
CAT#: AFC-TAB-103
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. It is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like , the antibody targets the interleukins 12 and 23.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- FC, IP, ELISA, Neut, FuncS
- Conjugate
- Unconjugated
- Generic Name
- Briakinumab
- Related Disease
- Crohn's disease (CD)
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- IL12B; interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40); NKSF2; interleukin-12 subunit beta; CLMF; CLMF2
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for AFC-TAB-103. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Biosimilar Overview
Please refer to Briakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Briakinumab.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Briakinumab"
Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab)Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221)Briakinumab is a human anti-IL-12 monoclonal antibody being developed for T-cell-driven autoimmune diseases, aiming at treating psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders. The DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221) is an anti-drug antibody (ADA) against Briakinumab. This drug-based antibody is raised in mice immunized with the Briakinumab. The anti-Briakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Briakinumab in samples.
See other products for "IL12+IL23"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1410-VHH | Recombinant Anti-Human IL12+IL23 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-103 | Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG1 - lambda |
| TAB-063 | Anti-Human IL12+IL23 Recombinant Antibody (Ustekinumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-063 | Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-063) | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
-2.png)
Application: Neut, ELISA, IF, IP, FuncS, FC, WB
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: ELISA, FC, WB, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, Inhib, FuncS
-2.png)
Application: WB, ELISA, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
